TEL-AVIV, Israel and RALEIGH, N.C. - RedHill Biopharma Ltd. (NASDAQ: NASDAQ:RDHL), a specialty biopharmaceutical company with a market capitalization of $7.53 million, today announced the initiation ...

Israeli pharmaceutical company RedHill Biopharma has initiated a placebo-controlled Phase II trial to assess the combination ...

RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced ...

(RTTNews) - RedHill Biopharma (RDHL) Tuesday announced that it has launched a Phase 2 trial to assess opaganib's ability to enhance darolutamide in treating metastatic castrate-resistant prostate ...

RedHill Biopharma (RDHL) announced the initiation of a Phase 2 clinical study to evaluate the efficacy of its opaganib candidate in combination ...

Researchers will use a lipidomic biomarker test to select patients with a poor prognosis who may benefit from an investigational combination therapy.

The phase 2/3 trial also showed that opaganib – an oral sphingosine kinase-2 (SK2) inhibitor – improved survival by 70% by day 42 compared to placebo when given on top of standard care ...

RedHill’s own COVID drug opaganib is currently in phase 2/3 trials, with recently reported clinical data showing a greater improvement in the proportion of patients no longer requiring oxygen ...

Preliminary data from the non-powered U.S. Phase 2 study of 40 hospitalized patients shows that orally-administered opaganib was safe, with no material safety differences between opaganib and control ...

RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced positive results from new in vivo studies of opaganib[1] as a treatment ...

Stock analysts at StockNews.com initiated coverage on shares of RedHill Biopharma (NASDAQ:RDHL – Get Free Report) in a research note issued to investors on Friday. The firm set a “hold” rating on the ...

The 80-patient placebo-controlled randomized Phase 2 study will evaluate the efficacy of opaganib in combination with Bayer's darolutamide in men with metastatic castrate-resistant ...